Archives
International Journal of Zoology and Applied Biosciences Research Article
Mucormycosis in post Covid-19 patients: emerging threat and clinical challenges in India
Vijaya Krishanan, Mahalakshmi Rajavelu, Thangasubha T, Selva Durai and Sujitha K
Year : 2025 | Pages: 30-32
Received on: 10/09/2025
Revised on: 20/10/2025
Accepted on: 26/10/2025
Published on: 10/11/2025
-
Vijaya Krishanan, Mahalakshmi Rajavelu, Thangasubha T, Selva Durai and Sujitha K ( 2025).
Mucormycosis in post Covid-19 patients: emerging threat and clinical challenges in India
. International Journal of Zoology and Applied Biosciences, 10( 6), 30-32.
-
click to view the cite format
Abstract
Mucormycosis, an opportunistic and aggressive fungal infection caused by fungi of the order Mucorales, has emerged as a serious complication in post–COVID-19 patients, particularly in India. The disease is non-communicable but is triggered by inhalation of fungal spores, which are ubiquitous in the environment. The widespread use of corticosteroids in COVID-19 management, coupled with uncontrolled diabetes mellitus and immune suppression, has significantly increased susceptibility. This review consolidates recent literature on the epidemiology, pathophysiology, and clinical management of COVID-19–associated mucormycosis (CAM) in India. It further explores antifungal treatment options such as liposomal amphotericin B, posaconazole, and isavuconazole, while addressing public-health challenges in surveillance and awareness. Early diagnosis and multidisciplinary interventions remain critical for reducing morbidity and mortality. Strengthened health-system preparedness, rational steroid use, and diabetes control are imperative to mitigate future mucormycosis outbreaks in post-pandemic India.
Keywords
COVID-19, Mucormycosis, Diabetes mellitus, Fungal infection, Corticosteroid therapy.
-
Full Article PDF (
20)
- View HTML Article
Copy Rights
© The Author(s) 2025. This article is published by International Journal of Zoology and Applied Biosciences under the terms of the Creative Commons Attribution 4.0 International License (creativecommons.org), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
